Yestar Health (02393) flags ≥RMB65.00 million FY2025 loss, reversing from RMB903.50 million profit

Bulletin Express

Mar 19

Yestar Healthcare Holdings Company Limited (“Yestar Health”; 02393.HK) has issued a profit warning, stating that preliminary unaudited figures point to a consolidated net loss of no less than RMB65.00 million for the financial year ended 31 December 2025 (FY2025). This compares with a net profit of RMB903.50 million in FY2024.

Management attributes the expected swing to two main factors:

1. FY2024 booked a one-off gain of approximately RMB1.08 billion from the discounted redemption of senior notes due 2026, a gain that will not recur in FY2025. 2. Impairment losses on non-financial assets are anticipated for FY2025.

The audited FY2025 results are scheduled for release on 27 March 2026. The board cautions investors that the current figures are based on internal management accounts and remain subject to further review and potential adjustment. Shareholders and potential investors are advised to act prudently when dealing in the company’s shares.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/1123520848"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1123520848\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1123520848?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-03-19 23:02","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1123520848","market":"hk","top_or_hot":-1,"title":"Yestar Health (02393) flags ≥RMB65.00 million FY2025 loss, reversing from RMB903.50 million profit","media":"Bulletin Express","content":"<p>Yestar Healthcare Holdings Company Limited (“Yestar Health”; 02393.HK) has issued a profit warning, stating that preliminary unaudited figures point to a consolidated net loss of no less than RMB65.00 million for the financial year ended 31 December 2025 (FY2025). This compares with a net profit of RMB903.50 million in FY2024.</p>\n<p>Management attributes the expected swing to two main factors:</p>\n<p>1. FY2024 booked a one-off gain of approximately RMB1.08 billion from the discounted redemption of senior notes due 2026, a gain that will not recur in FY2025.  \n2. Impairment losses on non-financial assets are anticipated for FY2025.</p>\n<p>The audited FY2025 results are scheduled for release on 27 March 2026. The board cautions investors that the current figures are based on internal management accounts and remain subject to further review and potential adjustment. Shareholders and potential investors are advised to act prudently when dealing in the company’s shares.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Yestar Health (02393) flags ≥RMB65.00 million FY2025 loss, reversing from RMB903.50 million profit</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nYestar Health (02393) flags ≥RMB65.00 million FY2025 loss, reversing from RMB903.50 million profit\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1053168898\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Bulletin Express </p>\n<p class=\"h-time\">2026-03-19 23:02</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Yestar Healthcare Holdings Company Limited (“Yestar Health”; 02393.HK) has issued a profit warning, stating that preliminary unaudited figures point to a consolidated net loss of no less than RMB65.00 million for the financial year ended 31 December 2025 (FY2025). This compares with a net profit of RMB903.50 million in FY2024.</p>\n<p>Management attributes the expected swing to two main factors:</p>\n<p>1. FY2024 booked a one-off gain of approximately RMB1.08 billion from the discounted redemption of senior notes due 2026, a gain that will not recur in FY2025.  \n2. Impairment losses on non-financial assets are anticipated for FY2025.</p>\n<p>The audited FY2025 results are scheduled for release on 27 March 2026. The board cautions investors that the current figures are based on internal management accounts and remain subject to further review and potential adjustment. Shareholders and potential investors are advised to act prudently when dealing in the company’s shares.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"02393","symbol_name":"巨星医疗控股","start_time":0,"source_url":"","article_id":"1123520848","we_media_id":"1053168898","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1123520848","pubTimestamp":1773932557,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Bulletin Express","introduction":"Full Coverage of HK & US Stock Announcements","home_visible":1,"id":"1053168898","head_image":"https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e"},"summary":"Yestar Healthcare Holdings Company Limited (“Yestar Health”; 02393.HK) has issued a profit warning, stating that preliminary unaudited figures point to a consolidated net loss of no less than...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"02393":"巨星医疗控股"},"translate_title":"巨星健康(02393)2025财年亏损≥人民币6500万元，从利润人民币90350万元转回","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02393":1},"content_text":"Yestar Healthcare Holdings Company Limited (“Yestar Health”; 02393.HK) has issued a profit warning, stating that preliminary unaudited figures point to a consolidated net loss of no less than RMB65.00 million for the financial year ended 31 December 2025 (FY2025). This compares with a net profit of RMB903.50 million in FY2024.\nManagement attributes the expected swing to two main factors:\n1. FY2024 booked a one-off gain of approximately RMB1.08 billion from the discounted redemption of senior notes due 2026, a gain that will not recur in FY2025.  \n2. Impairment losses on non-financial assets are anticipated for FY2025.\nThe audited FY2025 results are scheduled for release on 27 March 2026. The board cautions investors that the current figures are based on internal management accounts and remain subject to further review and potential adjustment. Shareholders and potential investors are advised to act prudently when dealing in the company’s shares.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-2","news_tag":"dataReport,SGX","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}